BRIEF-Northstrive Biosciences plans meeting with FDA for its new obesity reducing therapy

Reuters
10 Mar
BRIEF-Northstrive Biosciences plans meeting with FDA for its new obesity reducing therapy

March 10 (Reuters) - PMGC Holdings Inc ELAB.O:

  • NORTHSTRIVE BIOSCIENCES INC. SCHEDULES PRE-IND MEETING WITH FDA FOR EL-22, AN OBESITY THERAPY TARGETING FAT LOSS AND MUSCLE PRESERVATION IN COMBINATION WITH GLP-1

  • NORTHSTRIVE BIOSCIENCES : SCHEDULED A PRE-IND MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION FOR APRIL 23, 2025

Source text: nGNX7B0PkG

Further company coverage: ELAB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10